The financials
Mirum Pharmaceuticals, Inc. by the numbers
Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $176M in Q2 2026 (quarter ended June 30, 2026), up 38% from the same quarter a year earlier. That came with net loss of $67M. For the full year FY2025, revenue was $521M (+55% year on year) and net income −$23M. Its largest product in 2026-Q1 was Livmarli at $114M, 71% of the disclosed total, just ahead of Bile Acid Medicines at 29%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $176M | $128M | +38% |
| Operating income | −$43M | −$5.0M | n/a |
| Net income | −$67M | −$5.9M | n/a |
| Diluted EPS | −$1.06 | −$0.12 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Livmarli | $114M | 71% |
| Bile Acid Medicines | $46M | 29% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $159.9M (+20%)
Livmarli grew +55% year on yearBile Acid Medicines +20% year on year
Segment Latestquarter on quarteryear on year
- Livmarli$113.8M$113.8MQoQ +23%year on year +55%+23%+55%
- Bile Acid Medicines$46.1M$46.1MQoQ +13%year on year +20%+13%+20%
- License And Other--QoQ -year on year ---